作者: DAVID G. COGAN
DOI: 10.1001/ARCHOPHT.1965.00970040219016
关键词:
摘要: Our concept of myasthenia gravis has evolved from: (1) its recognition as a clinical syndrome first enunciated by T. Willis in the 17th century 1 ; (2) more precise exposition Erb 1879 and Goldflam 1893 (whence designation Erb-Goldflam disease); (3) an effective treatment anticholinesterase agents introduced Walker 1934 2 (4) pharmacodiagnosis means intramuscular neostigmine (Prostigmine), described Viets Schwab 1935, 3 improved later use intravenous edrophonium chloride (Tensilon) 4 (5) curious association with thymic hyperplasia sometimes thymomas 5,6 (6) significantly frequent myasthenic dysthyroidism, bronchogenic carcinoma, 7 some autoimmune diseases 8 (7) characteristic fatigue pattern demonstrable electromyography, which may be diagnostic significance. 9 The extraocular muscles orbicularis oculi are most commonly affected. Approximately half